On March 16, 2026, Dare Bioscience, Inc. announced the successful closing of its previously announced Regulation A offering, which involved the issuance of 43,050 Investor Units. Each Investor Unit consists of one share of Series A Convertible Preferred Stock and two warrants, each allowing the purchase of one share of common stock. The offering price for each Investor Unit was set at $5.00, resulting in a total issuance of 43,050 shares of Series A Preferred Stock and warrants to purchase up to 86,100 shares of common stock. This offering was conducted under the offering statement on Form 1-A, which was qualified by the U.S. Securities and Exchange Commission on January 5, 2026. The details regarding the terms of conversion and exercise of the Series A Preferred Stock and Investor Warrants were previously disclosed in a Current Report on Form 8-K filed on January 29, 2026. The completion of this offering is expected to enhance the company's liquidity position, providing additional capital to support its operational and strategic initiatives. However, the issuance of new shares may lead to dilution for existing shareholders, which is a consideration for investors moving forward.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.